tbuckley/cabot-search huggingface dataset:
Family Income Supplements and Development of Psychiatric and Substance Use Disorders Among an American Indian Population—Reply
Authors: E. Jane Costello
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutational landscape of ovarian cancers (OC) identified by prospective clinical sequencing in a nationwide cancer network.
Authors: Julian Schink, Ricardo H. Alvarez, Julia Andrea Elvin, Amber Moran, Rebecca Rollins, John P. Geisler, Justin Chura, David McIntosh, Natalie Godbee, Bradford A. Tan, Maurie Markman
Journal: Journal of Clinical Oncology (2019)

e17067 Background: Tumor genomic profiling is a critical component of precision oncology allowing the detection of genomic alterations (GA) that have the potential to be targeted therapeutically. We present an analysis of comprehensive genomic profiling (CGP) of a large series of OC assayed in a nationwide cancer network. Methods: 449 Pts with advanced OC underwent CGP with hybrid capture of up to 406 cancer-related genes on tumor tissue or for 62 genes on circulating tumor DNA ordered during clinical care for treatment decision-making between 01-2013 to 05-2018. Clinically relevant (CR) GA were defined as associated with targeted therapies or mechanism-driven clinical trials. Treatment histories for the 449 patients were obtained with IRB-approved retrospective review. Results: Median age was 56 years (range, 23-83), 71% were Caucasian. GA were identified in 94% (420/449) of OC, of which 283 (63%) had a clinically relevant genomic alteration (CRGA). 24.0% in HRD ( BRCA1/2, ATM, PALB2, BRIP1). CRGA in other potentially targetable pathways were identified: 48.0% MEK pathway ( KRAS, NRAS, HRAS, BRAF, RAF1, GNAS, NF1, NF2) CRGA, 33.5% PI3K/AKT/mTOR pathway ( PIK3CA, AKT1/2/3, PIK3R1, PTEN, MTOR, STK11, FBXW7), and 10.6% in ERBB ( ERBB2, ERBB3, ERBB4, EGFR). All OC tested were microsatellite stable and only one patient had a tumor mutational burden &gt; 20 muts/Mb. 21% (59/283) of OC patients were ordered a genomically-matched treatment, 58% (37/64) were agents that were FDA approved in a different tumor type, and 17% (11/64) through referral to a matched mechanism driven clinical trial. With access to the clinical trial TAPUR, the frequency of matched treatment through clinical trials increased over time from 2013 to 2018. For the off label non-study population the median PFS was 19 weeks, and the median OS was 34 weeks. Conclusions: In a large series of OC assayed with CGP, 21% of pts received matched treatment, which was predominantly targeted therapy. The comprehensive sensitive and unbiased nature of CGP, coupled with a multidisciplinary molecular tumor board and staff dedicated to genomic interpretation, assisted in achieving a high frequency of patients’ participation in clinical trials and gene-directed treatment.
Book Review Textbook of Pediatrics . By J. P. Crozer Griffith, M.D., Ph.D.; and A. Graeme Mitchell, M.D. Third edition, revised and reset. 8°, cloth, 991 pp., with 220 illustrations and 66 tables. Philadelphia: W. B. Saunders Company, 1941. $10.00.
Journal: New England Journal of Medicine (1941)
POSTERIOR SINUS INFECTION WITH OPTIC NERVE INVOLVEMENT
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Regulating Abortions
Authors: S Shapiro
Journal: New England Journal of Medicine (1973)

The lack of clinical guidelines in the regulation of abortion following the Supreme Court's decision allowing abortion is discussed. Regarding first trimester abortions, the Court merely stipulated that the procedure must be performed by a licensed physician. Although few would disagree that adequate social services and contraceptive counseling should accompany abortion procedures, there is no legal guarantee that they would be provided. Recently, the Advisory Committee on Abortion of the Massachusetts Medical Society proposed guidelines to ensure that high standards of medical care are followed in abortion cases, upon which final action is pending. It is urged that the medical profession act to establish guidelines for the care of abortion patients, not only to ensure the health and well-being of the woman, but also to demonstrate that the medical profession is capable of acting responsibly in the regulation of its own practice.
Blood Transfusion
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What is the definition of misclassification in patients with grade group 2 prostate cancer eligible for active surveillance and diagnosed with MRI targeted biopsy? A multi-institutional analysis with pathological confirmation
Authors: G. Gandaglia, E. Mazzone, A. Stabile, S. Scuderi, F. Barletta, D. Robesti, G. Ploussard, R.G. Rahota, M. Valerio, R. Campi, A. Mari, G. Marra, A. Marquis, J.B. Beavaul, M. Roumiguié, L. Afferi, M. Moschini, P. Gontero, H. Tuo, N. Fossati, F. Montorsi, A. Briganti
Journal: European Urology (2021)
PARAFFINOMA
Authors: DOUGLASS W. MONTGOMERY
Journal: JAMA (1926)

We have seven histories of paraffinomas, of which two are of more than ordinary interest. All the victims were women. The ages of six of them were, respectively, 43, 38, 44, 71, 41, and, finally, as a surprise, 20 years. One of the especially interesting cases was that of a woman, aged 43, who consulted us, Sept. 17, 1912, and who began to get paraffin injections into the face the preceding May. The last was given, June 10. Therefore, she consulted us three months after the last injection. Two days after this last injection, she caught "cold" in the face in going to the beach, and the site of the injections became swollen, red and inflamed; ever since, this irritation had recurred about every ten days. When the patient consulted us there was a dark red, irregular shaped induration of the left cheek, with much edema of the left lower
Lament for a Friend
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Childhood asthma: treatment and severity
Authors: A D Milner
Journal: BMJ (1982)

Childhood asthma: treatment and severity Few diseases have such a range of severity as childhood asthma.At one extreme are the many children with only mild and infrequent wheezing.At the other end are those with severe chronic asthma making them respiratory cripples.Clearly those with trivial symptoms should not receive the potentially toxic drugs which are entirely justified in those with chronic severe asthma.The severity of the disease must therefore be assessed before treatment is started.Most children with asthma have occasional mild attacks, forming grades A and B as described by Williams and McNicol.1These children grow normally, miss little school, and should be able to take part in all physical activities.Chest deformity is minimal, if present at all, and lung function (as assessed by peak flow or spirometry on routine visits to the clinic or surgery) is usually normal.Many will respond entirely satisfactorily to treatment with oral beta-2 stimulants.2Regular treatment with sodium cromoglycate or theophylline is not indicated-and if prescribed is unlikely to be taken in the long term.Alternatively, these children can be helped by taking inhaled bronchodilator drugs as soon as symptoms begin, either in the form of salbutamol Rotohaler3 or, in those over the age of 7 and sufficiently well co-ordinated, one of the beta-2 pressurised aerosols.The chances of any of these children becoming critically ill are remote, and most will either grow out of their symptoms by puberty or show considerable improvement.The remaining asthmatic children are more worrying-but they form less than 1%1 ofthe child population.These children have frequent troublesome attacks which interfere with their social and educational life.Indeed, if not adequately treated the disease will tend to isolate the child.Nevertheless, many such children have periods when they are asymptomatic and are apparently entirely well.These patients, who are categorised as group C,1 again should have no growth retardation but they may have some chest deformity with bilateral Harrison's sulci-particularly at the younger end of the age range.Lung function tests will show wide variation ranging from normality to severe airways obstruction.Some of these children may have severe life-threatening attacks, and all require regular maintenance treatment.Usually beta-2-stimulant drugs are insufficient.The alternatives are oral theophylline, using a slow-release preparation which can be given every eight to 12 hours,4 or thrice-daily sodium cromoglycate given by Spinhaler.
Empyema in childhood
Authors: D. B. Groff
Journal: JAMA (1966)

The introduction of antibiotics two decades ago made it appear that empyema would pass into history as a surgical and medical problem. However, there has been an increase in the incidence of childhood empyema in recent years.<sup>1-3</sup>Today, childhood empyema is a common complication of staphylococcal pneumonia; Koch and coworkers reported a 74% incidence of empyema in 83 cases of staphylococcal pneumonia in children.<sup>4</sup>Kevy and Lowe reported empyema associated with 10 of 11 cases of streptococcal pneumonia.<sup>5</sup>In spite of this increase in the incidence of childhood empyema, many surgeons who treat adult empyema are not familiar with the course of this disease in children. Empyema in children is almost always seen following a primary pulmonary infection. Since the introduction of antibiotics, empyema in adults is most often associated with malignancy or an operative procedure. In addition, the management and prognosis of childhood empyema differ from
Mannose-Binding Lectin in Pre-Menopausal Women with Recurrent Urinary Tract Infections
Authors: Raul Colodner, Orna Nitzan, Bibiana Chazan, Hana Edelstein, Raul Raz
Journal: Clinical Microbiology and Infection (2009)

<h2>Abstract</h2> Mannose-binding lectin (MBL) comprises an oligomeric serum protein that is a member of the collectin class of the C-type lectin super-family. Its deficiency is genetically determined and confers predisposition to recurrent infections as well as increased infection severity. This correlation has been demonstrated in recurrent furunculosis caused by <i>Staphylococcus aureus</i>, and in pneumococcal and <i>Candida</i> infections. The present study aimed to determine whether there is a correlation between MBL serum levels and recurrent urinary tact infections (UTI) in pre-menopausal women. The present aged-matched double-blind controlled study was conducted in 100 pre-menopausal adult women: 50 who suffered from recurrent UTI and 50 without UTI. The MBL concentration was measured in a single serum sample from each patient using an enzyme-linked immunosorbent assay. MBL serum levels [median (range)] were 2500 (4–12 000) ng/mL and 2105 (4–22 800) ng/mL for the research and control groups, respectively. The results from the two groups were compared and were not statistically different (p 0.4). According to these results, MBL serum levels are not associated with an increased risk for recurrent UTI in pre-menopausal women.
ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a P2 study in Indian women with recurrent/refractory cervical cancer.
Authors: Robert G. Petit, Partha Basu
Journal: Journal of Clinical Oncology (2013)

5529 Background: ADXS11-001 immunotherapy is a live attenuated Listeria monocytogenes (Lm) bioengineered to secrete a HPV16-E7 fusion protein targeting HPV transformed cells. The Lm vector serves as its own adjuvant and infects APC where it naturally cross presents, stimulating both MHC class 1 and 2 pathways resulting in specific T-cell immunity to tumors. Here we describe the preliminary survival data associated with ADXS11-001 administration in Lm-LLO-E7-015, a randomized P2 study being conducted in India in 110 patients with recurrent/refractory cervical cancer who have been treated previously with chemotherapy, radiotherapy or both. Methods: Patients were randomized to either 3 doses of ADXS11-001 at 1 x 10 9 cfu or 4 doses of ADXS11-001 at 1 x 10 9 cfu with cisplatin chemotherapy. Naprosyn and oral promethazine were given as premedications and a course of ampicillin was given 72h after infusion. Patients received CT scans at baseline and 3, 6, 9, 12 and 18 months. The primary endpoint is overall survival. Results: As of February 2013, the trial has completed enrollment and 110 patients have received 264 doses of ADXS11-001. The percentage of patients alive at 6 months is 63% (67/107); at 9 months is 46% (49/106); at 12 months is 34% (30/87) and at 18 months is 15% (8/54). Tumor responses have been observed in both treatment arms with 6 CRs and 6 PRs; 36 additional patients had stable disease &gt; 3 months, for a disease control rate of 44% (48/110). Activity against different high risk HPV strains has been observed. Three serious adverse events and 69 mild-moderate adverse events possibly related/related to ADXS11-001 treatment have been reported in 41% (45/110) of patients. The non-serious adverse events consisted predominately of transient, non-cumulative flu-like symptoms associated with infusion that either resolved on their own or responded to symptomatic treatment. Conclusions: ADXS11-001 can be safely administered to patients with advanced cancer alone and in combination with chemotherapy. ADXS11-001 is well tolerated and presents a predictable and manageable safety profile. Final 12-month OS, updated safety and translational analyses will be presented at the meeting.
A Textbook ot Histology
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
“Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease.” Laurent Savale, Anoosha Habibi, François Lionnet, Bernard Maitre, Vincent Cottin, Xavier Jais, Ari Chaouat, Elise Artaud-Macari, Matthieu Canuet, Grégoire Prevot, Christelle Chantalat-Auger, David Montani, Olivier Sitbon, Fréderic Galacteros, Gérald Simonneau, Florence Parent, Pablo Bartolucci and Marc Humbert.<i>Eur Respir J</i>2019; 54: 1900585.
Authors: Laurent Savale, Anoosha Habibi, François Lionnet, Bernard Maitre, Vincent Cottin, Xavier Jais, Ari Chaouat, Elise Artaud-Macari, Matthieu Canuet, Grégoire Prevot, Christelle Chantalat-Auger, David Montani, Olivier Sitbon, Fréderic Galacteros, Gérald Simonneau, Florence Parent, Pablo Bartolucci
Journal: European Respiratory Journal (2020)
Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis
Authors: F Violi
Journal: Hepatology (1993)

This study explored the relationship between clotting activation and tissue plasminogen activator and its inhibitor in cirrhotic patients with different degrees of liver failure. Sixty-seven patients (40 men, 27 women; age = 31–77 yr) with cirrhosis diagnosed by liver biopsy were divided into three subgroups (A, B and C) on the basis of Child-Pugh classification. Tissue plasminogen activator antigen and activity, plasminogen activator inhibitor antigen and activity, fibrin/fibrinogen degradation products, and D-dimer were measured in each patient. Forty-two patients with normal levels of fibrin/fibrinogen degradation products and D-dimer showed significant progressive decreases of plasminogen activator inhibitor antigen levels (p < 0.01) and activity (p < 0.0001) from class A to class C. This decrease was significantly related to prothrombin time (p < 0.003). Tissue plasminogen activator values were not different in the three Child classes. Twenty-five patients (7 class B and 18 class C) with high circulating values of fibrin/fibrinogen degradation products and D-dimer had higher values of tissue plasminogen activator antigen (20.0 ± 10.1 ng/ml vs. 5.9 ± 3.0 ng/ml; p < 0.0001) and activity (6.9 ± 2.2 U/ml vs. 2.1 ± 1.3 U/ml;p < 0.0001) and lower values of plasminogen activator inhibitor antigen (6.9 ± 4.1 ng/ml vs. 14.8 ± 5.6 ng/ml; p < 0.0001) and activity (4.1 ± 2.8 U/ml vs. 9.8 ± 3.7 U/ml; p < 0.0001) than did patients with normal values of fibrin/fibrinogen degradation products and D-dimer. We conclude that cirrhotic patients without systemic signs of hyperfibrinolysis exhibited progressive decreases of plasminogen activator inhibitor levels, suggesting that its blood levels are strongly related to liver function. The clear-cut imbalance between tissue plasminogen activator and plasminogen activator inhibitor in patients with high circulating levels of D–dimer indicates that hyperfibrinolysis may be due mainly to clotting activation. (HEPATOLOGY 1993;17:78–83.)
Allied health education and accreditation
Authors: G. C. Gupta
Journal: JAMA (1990)

<h3>STRUCTURE AND FUNCTION OF THE COMMITTEE ON ALLIED HEALTH EDUCATION AND ACCREDITATION</h3> For more than 50 years, the American Medical Association (AMA) and its members have recognized the value of actively participating in and promoting quality education for allied health personnel. This participation is increasingly important as it becomes more difficult to maintain an adequate supply of qualified professionals who complement, facilitate, or assist physicians as they provide health care services to the public. The history of specific AMA activities related to allied health education and accreditation is recorded in pastMedical Educationissues of<i>The Journal of the American Medical Association</i>. The current era began in 1976 with the establishment of the AMA Committee on Allied Health Education and Accreditation (CAHEA), a 14-member accrediting body staffed by the Division of Allied Health Education and Accreditation (DAHEA) and its three departments. The membership of CAHEA reflects the communities that hold
Untargeted Metabolomic Profiling Identifies Disease-Specific Pathways in Food Allergy and Asthma
Authors: Elena Crestani, Jonathan Leirer, Alison Motsinger-Reif, Wanda Phipatanakul, Rima Kaddurah-Daouk, Talal A. Chatila
Journal: Journal of Allergy and Clinical Immunology (2019)